A Study to Investigate the Safety, Tolerability, and Pharmacokinetics of ALS-008176 in Healthy Japanese Adult Participants

Condition:   Respiratory Syncytial Virus Infections
Interventions:   Drug: ALS-008176 (250 mg);   Drug: ALS-008176 (500 mg);   Drug: ALS-008176 (750 mg);   Other: Placebo
Sponsor:   Janssen Pharmaceutical K.K.
Completed - verified July 2016
Source: 
A Study to Investigate the Safety, Tolerability, and Pharmacokinetics of ALS-008176 in Healthy Japanese Adult Participants
News Type: 
Clinical Trials